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Role of excess volume in the pathophysiology of hypertension
in chronic kidney disease.
Background. The pathophysiology of hypertension in pa-
tients with chronic kidney disease (CKD) is largely attributed
to positive sodium balance. It is unclear how loop diuretics
affect fluid volume compartments, especially with respect to
their antihypertensive effect.
Methods. Subjects with CKD were administered a single
therapeutically equivalent dose of an oral loop diuretic (furose-
mide or torsemide in randomized crossover design). We mea-
sured acute volume changes over 12 hours using biophysical
and hormonal biomarkers and then 24-hour ambulatory blood
pressure after daily diuretic therapy for 3 weeks.
Results. Single-dose administration of loop diuretic de-
creased extracellular water (ECW) by 1.7 L [95% confidence
interval (95% CI) 1.2, 2.2, P 0.001], total body water (TBW)
by 1.2 L (95% CI 0.5, 1.9, P  0.001), and increased natural
log (ln) plasma renin activity (PRA) from 1.2  1.3 ng/mL/
hour to0.5 1.5 ng/mL/hour (P 0.001). Daily loop diuretic
administration resulted in reduced ECW from 24.2  6.4 L to
22.3 5.2 L (P 0.02) and TBW from 54.3 12.7 L to 51.6
11.9 L (P 0.001) in 1 week. After 3 weeks of diuretic therapy,
whereas ECW reduction persisted at 22.8  5.1 L (P  0.05),
TBW trended toward baseline level at 52.7 11.8 L. A concom-
itant increase in ln PRA from –1.0  1.3 ng/mL/hour to 0.4 
1.9 ng/mL/hour (P  0.001) and ln plasma aldosterone (PA)
from 2.0  0.8 ng/dL to 2.3  0.8 ng/dL (P  0.005) and fall
in ln brain natriuretic peptide (BNP) from 4.3  0.9 pg/mL to
3.7  1.0 pg/mL (P  0.01) were seen at 1 week. Despite a
trend toward restoration of TBW, changes in hormonal bio-
markers were maintained at 3 weeks. Over these 3 weeks,
furosemide reduced 24-hour ambulatory blood pressure from
147  17/78  11 mm Hg to 138  21/74  12 mm Hg (P 
0.021) and torsemide reduced it from 143 18/75 10 mm Hg
to 133  19/71  10 mm Hg (P  0.007).
Conclusion. Patients with CKD have elevated extracellular
fluid volume that can be corrected acutely with loop diuretics.
Persistent diuretic use results in dynamic changes in ECW and
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other body fluid compartments that translate into chronic blood
pressure reduction.
Diuretics have reemerged as important therapeutic
agents in controlling morbidity and mortality associated
with hypertension [1]. However, limited data exist on
how blood pressure reduction occurs with diuretic use
in patients with hypertension. Kidney function appears
to be important for the antihypertensive effects of diuret-
ics, as these drugs are ineffective in lowering blood pres-
sure in anephric patients. There is a paucity of data on
how blood pressure lowering occurs with diuretic use in
patients with impaired renal function.
According to the Third National Health and Nutrition
Examination Survey (NHANES III), there are approxi-
mately 63 million individuals in the United States with
mild or moderate chronic kidney disease (CKD) [2].
Hypertension is a frequently observed disorder in these
individuals, ranging in prevalence from 60% to 100%
[3] and is associated with significant cardiovascular mor-
bidity and mortality. The presence of hypertension in
CKD is widely believed to be a manifestation of positive
sodium balance.
We have previously reported effective blood pressure
reduction and natriuresis with the loop diuretics torse-
mide and furosemide in a randomized double-blind con-
trolled trial. No differences between diuretics were seen
with respect to natriuresis or antihypertensive response
[4]. We hypothesized that studying the time course of
volume changes together with ambulatory blood pres-
sures would implicate the central role of dynamic changes
in volume compartments with the pathogenesis of hyper-
tension in patients with CKD.
METHODS
Subjects
Study design and primary results of the study have
been previously reported [4]. Briefly, a randomized, fixed-
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dose, double-blind, single-center, crossover trial was con-
ducted involving single-dose and multiple-dose diuretic
administration in a General Clinical Research Center
(GCRC). Study participants were at least 18 years of
age, had CKD as determined by serum creatinine greater
than 1.4 mg/dL, and hypertension (average of three sit-
ting cuff blood pressure  130/80 mm Hg or 125/75
mm Hg if the subject had proteinuria greater than 1
g/day) with or without edema. Subjects with moderate
to severe CKD [glomerular filtration rate (GFR) less
than 30 mL/min], symptomatic congestive heart failure,
uncontrolled hypertension (blood pressure greater than
180/110 mm Hg), stroke or myocardial infarction within
3 months, or chronic liver disease were excluded.
The protocol was approved by the Institutional Re-
view Board at Indiana University School of Medicine
and the Richard L. Roudebush VA Medical Center.
Written informed consent was obtained from each sub-
ject prior to study participation.
Inpatient single-dose study
From 3 days prior to admission to the GCRC and until
the completion of the sodium balance study, subjects
consumed a study diet prepared by the metabolic kitchen
consisting of daily intake of 200 mEq sodium, 1 g calcium,
constant potassium (2.4 to 3.8 g, based on total caloric
requirement) and 80 g protein. After admission to GCRC,
on days 3 and 6, the subjects received a single oral
masked dose of either torsemide 100 mg or furosemide
200 mg with water (10 mL/kg) to encourage diuresis.
GFR was assessed on study drug days by plasma clear-
ance of an intravenous bolus of iothalamate [5]. Plasma
brain natriuretic peptide (BNP) was measured at base-
line and 12 hours poststudy drug dosing. Plasma renin
activity (PRA) and plasma aldosterone (PA) were mea-
sured at baseline, 3 hours, and 12 hours after administra-
tion of diuretics. Measurements of body composition by
bioelectric impedance analysis (BIA) were obtained at
baseline, 3 hours, and 6 hours postdrug dosing. Blood
draws and BIA measurements followed 30 minutes of
supine rest. The subjects were discharged on day 7 and
instructed not to take any diuretic during the washout
phase.
Outpatient multiple-dose study
After 1 week of abstaining from diuretics, subjects
were given a randomized, blinded, fixed-dose, 3-week
course of either torsemide 40 mg daily in a single dose
or furosemide 80 mg daily in two divided doses. Ambula-
tory blood pressure measurements over 24 hours were
performed at baseline and 3 weeks of therapy. Plasma
concentrations of BNP, PRA, and PA, and measurement
of body composition by BIA were obtained at baseline,
1 week, and 3 weeks of therapy. Blood draws and BIA
measurements followed 30 minutes of seated rest. The
subject then entered a 2-week washout period followed
by therapy with the second fixed dose, blinded drug with
identical blood pressure and volume measurements.
Laboratory analysis
Urine sodium was measured by ion selective elec-
trodes using the Cobas Mira analyzer (Roche Diagnos-
tics, Indianapolis, IN, USA). Plasma clearance of a 3 mL
dose of intravenous iothalamate meglumine bolus (Con-
ray 60, Mallinckrodt Medical, Inc., St. Louis, MO, USA)
was used to measure GFR. Plasma samples were col-
lected at 2, 3, 6, 9, and 12 hours after the bolus and
iothalamate measured by high-performance liquid chro-
matography (HPLC) and GFR measured by plasma
clearance using first-order elimination kinetics [5].
Blood specimens were collected in ethylenediamine
tetraacetic acid (EDTA)-containing tubes. Plasma was
immediately separated and stored at –85C until analysis.
Plasma BNP was measured by fluorescence immuno-
assay (TriageBNP Test, Biosite Incorporated, San Diego,
CA, USA). Aldosterone concentration was measured by
radioimmunoassay (Diagnostic Products Corporation,
Los Angeles, CA, USA) and PRA was measured with
Clinical Assays GammaCoat radioimmunoassay kit (Dia-
Sorin, Stillwater, MN, USA).
Body composition was measured using a BIA-106
Spectrum II analyzer (RJL Systems, Inc., Clinton Twp.,
MI, USA) was used and data were collected using Weight
Manager version 2.0 software (RJL Systems, Inc.). The
technique of BIA involved introducing an imperceptible
800 A alternating current at 50 Khz through signal
introduction cables placed with pregelled electrodes on
the ulnar head and medial malleolus. Sensing electrodes
placed at the ipsilateral third metacarpal and second
metatarsal, determined the electrical resistance and re-
actance. The vector sum of resistance and reactance to
the electrical current equaled the impedance, which var-
ied in different biologic tissues. The BIA software used
these indices to determine body composition, including
extracellular water (ECW), intracellular water (ICW),
total body water (TBW), and lean body weight (LBW).
Ambulatory blood pressure measurements were re-
corded every 20 minutes during the day (6:00 a.m. to
10:00 p.m.) and every 30 minutes during the night (10:00
p.m. to 6:00 a.m.) using a Spacelabs 90207 ABP monitor
(SpaceLabs Medical, Inc., Redmond, WA, USA). Data
were analyzed using ABP Report Management System
software, version 1.03.05 (SpaceLabs Medical Inc.).
Statistical analysis
Data are reported as mean  SD, and a two-sided P
value of less than 0.05 was considered to be significant.
BNP, PRA, and PA were log transformed before analysis
to satisfy the normality assumption. The relationship
between GFR and biophysical and hormonal markers of
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volume status was analyzed using analysis of covariance
after accounting for the drug administered. Baseline,
intermediate, and posttreatment BNP, PRA, PA, and
BIA parameters were analyzed by multivariate repeated
measures analysis of variance for the single- and multi-
ple-dose study with diuretic as a categorical variable.
Contrast analysis was utilized to determine significances
of trends observed. Tukey honest significant test was
used for post hoc testing. All analyses were conducted
on Statistica for Windows, release 5.5 (StatSoft, Inc.,
Tulsa, OK, USA).
RESULTS
Study participants
Fourteen subjects satisfied the inclusion and exclusion
criteria and consented to participate in the study. The
mean age of this cohort was 67  11 years, 93% were
males, 43% were African Americans, 57% of subjects
had diabetes mellitus, and 21% had left ventricular hy-
pertrophy by Cornell voltage duration product on elec-
trocardiogram [6]. At baseline evaluation of these 14
subjects, 11 subjects were administered angiotensin-con-
verting enzyme (ACE) inhibitors or angiotensin II recep-
tor antagonists [angiotensin receptor blockers (ARBs)];
seven subjects were using beta blockers, and five subjects
were using calcium channel blockers. These medications
were continued throughout the study. Mean baseline
weight was 96 25 kg, blood pressure was 153 10/81
5 mm Hg, and sodium excretion was 184 54 mmol/day.
Mean GFR by iothalamate clearance was 45.1  16.6
mL/min.
All subjects completed the inpatient study and 12 sub-
jects completed the outpatient study. After a washout
period of 1 week, these 14 subjects received 3 weeks of
outpatient oral torsemide or furosemide with a 2-week
intervening washout period. One subject experienced
prerenal azotemia and required discontinuation of the
study medication after 1 week of therapy. Another devel-
oped a respiratory tract infection, received several doses
of diuretics, and was withdrawn from the study. Thus,
12 subjects entered the second phase of the outpatient
study. During the second phase, one subject developed
mild prerenal azotemia and hypotension, was changed
to half-dose therapy with resolution of abnormalities. All
12 subjects completed the second phase of the outpatient
study.
Influence of CKD on volume status markers
An inverse relationship was seen between GFR and
plasma BNP such that for 10 mL/min decline in GFR,
BNP increased 9.8 pg/mL (P  0.04). Other markers of
volume excess also negatively correlated with GFR. For
every 10 mL decline in GFR, ECW/LBW increased by
0.02 L (P 0.019), ECW/TBW increased by 0.02 L (P
Fig. 1. Brain natriuretic peptide (BNP) responses after single (A) and
multiple (B) doses of torsemide and furosemide therapy for each sub-
ject. Closed triangles represent treatment with torsemide; open triangles
represent treatment with furosemide. Box plots represent the median,
10th, 25th, 75th, and 90th percentiles of each data set. Ln is natural log.
0.02), ECW/ICW increased by 0.15 L (P  0.03), and
ICW increased by 2.4 L (P  0.01). PRA, PA, TBW,
ECW, LBW, resistance, and reactance showed no corre-
lation with GFR.
Influence of acute diuretic therapy on volume status
For torsemide, baseline natriuresis increased from
213  79 mEq/day to 398  142 mEq/day, a difference
of 185  137 mEq/day. After furosemide, natriuresis
increased from a baseline of 199 49 mEq/day to 357
96 mEq/day, a difference of 158  115 mEq/day. These
differences were not statistically significant between the
two diuretics. Thus, single-dose diuretic therapy pro-
duced a significant increase in natriuresis from baseline
(172  125 mEq/day) but did not produce a significant
change in plasma BNP (Fig. 1A). Despite an equivalent
of 1.2 L isotonic saline loss, no correlation was seen with
either a change in plasma BNP (P  0.53) or ECW/
LBW ratio (P  0.47).
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Table 1. BIA results for the single- and multiple-dose study
Single-dose study Multiple-dose study
Parameter Baseline Hour 3 Hour 6 Change/6 hours P Baseline Week 1 Week 3 P
Resistance ohms 461.887.2 477.597.4 487.197.9 25.4 (16.9,33.8) 0.001 419.084.3 441.492.0a 430.182.1 0.01
Reactance ohms 42.311.1 45.913.2 47.212.6 4.9 (3.5,6.3) 0.001 39.910.3 42.78.4 41.87.8 0.29
ECW L 21.75.9 20.55.8 20.05.4 1.7 (2.2, 2.2) 0.001 24.26.4 22.35.2b 22.85.1 0.05
ICW L 27.08.3 27.68.0 27.57.9 NA 0.10 29.67.4 28.19.3 29.47.6 0.17
TBW L 48.711.7 48.111.6 47.511.3 1.2 (1.9, 0.5) 0.001 54.312.7 51.611.9c 52.711.8b 0.005
ECW/ICW 0.90.6 0.80.4 0.80.3 NA 0.19 0.80.2 0.80.2 0.80.2 0.58
ECW/TBW 0.50.1 0.40.1 0.40.1 0.03 (0.04, 0.01) 0.005 0.40.1 0.40.0 0.40.1 0.52
LBW L 66.615.9 65.815.7 64.915.3 1.7 (2.6, 0.7) 0.001 72.118.1 68.717.2b 72.116.1d 0.005
Abbreviations are: ECW, extracellular water; ICW, intracellular water; TBW, total body water; LBW, lean body weight. Data are presented as mean  SD. NA
indicates contrast analysis not applicable due to lack of statistical significance by multivariate analysis of variance (ANOVA).
a P  0.005 versus baseline; b P  0.05 versus baseline; c P  0.001; d P  0.05 versus week 1 versus baseline by Tukey honest significant difference test
Table 2. Time course of volume markers
Single-dose study Multiple-dose study
Parameter Baseline Hour 3 Hour 12 P Baseline Week 1 Week 3 P
Ln BNP 3.851.01 NA 3.820.87 0.62 4.260.85 3.671.00a 3.690.97a 0.001
Ln PRA 1.191.32 0.511.51b 0.231.80b 0.001 0.991.34 0.411.91b 0.281.73b 0.002
Ln PA 1.831.06 2.060.96 1.881.24 0.12 2.010.76 2.340.76c 2.440.61b 0.001
Abbreviations are: BNP, brain natriuretic peptide; PRA, plasma renin activity; PA, plasma aldosterone; Ln, natural log.
a P  0.01 versus baseline; b P  0.001 versus baseline by Tukey honest difference test; c P  0.005 versus baseline
Single-dose administration of loop diuretic acutely in-
duced significant volume depletion as characterized by
1.3% decrease in body weight (P 0.001), and supported
by BIA findings shown in Table 1. Six hours after diuretic
administration, ECW decreased by 8% and TBW de-
creased by 2%, but ICW did not change. No time	 treat-
ment interaction was seen with measured parameters,
thus either diuretic produced a similar response. As
shown in Table 2, PRA increased by 97% at 3 hours
(P  0.001) and 161% at 12 hours (P  0.001) following
a single dose of diuretic. In contrast, PA did not change
in response to diuretic administration (ANOVA, P 
0.12). Serum potassium decreased by 5.5% over 12 hours
(P  0.01). Interestingly, small but significant decreases
in serum potassium were noted. Torsemide induced a
change in serum potassium from 4.2 to 4.0 mEq/L; furo-
semide induced a change of 4.4 to 4.2 mEq/L; overall,
the change was from 4.3 to 4.1 mEq/L. No supplemental
potassium was given, as these values were within the
normal range. No time	 treatment interaction was seen
for PRA, PA, and BNP.
Influence of chronic diuretic therapy on volume status
and blood pressure
Chronic diuretic therapy initially induced volume deple-
tion, followed by a trend toward restoration of volume
status (Table 1). Reduction in ECW occurred over 1
week from 24.2 to 22.3 L but was partially restored to
22.8 L over 3 weeks. Similarly, TBW reduced from 54.3
to 51.6 L over 1 week that was partly restored to 52.7 L
over 3 weeks. Changes in hormonal markers paralleled
BIA measurements. Plasma BNP significantly decreased
by 45% between baseline and week 1 and persisted at
week 3 with a net decrease of 43% (Fig. 1B) (Table 2).
PRA increased by 306% between baseline and week 1;
this significant effect persisted at week 3 with a net in-
crease of 258% (Fig. 2A) (Table 2). Similarly, PA in-
creased by 40% between baseline and week 1; this sig-
nificant effect persisted at week 3 (Fig. 2B) (Table 2).
Chronic diuretic treatment significantly reduced ambula-
tory systolic blood pressure from 144.8  17.3 mm Hg
at baseline to 135.3 19.8 mm Hg at week 3, a reduction
of 9.4  11.2 mm Hg. No time 	 treatment interaction
was seen for any of the parameters noted above. The
presence or absence of ACE inhibition or ARB usage
did not significantly influence the systolic blood pressure
reduction.
Most subjects did not experience the dipping phenom-
enon (experienced a night to day systolic blood pressure
ratio of 
 0.9) at baseline. In the furosemide treatment
period, two subjects were dippers at baseline; after 3
weeks of furosemide therapy, one subject remained a
dipper. In the torsemide treatment period, no subjects
were dippers at baseline; after 3 weeks of furosemide
therapy, two subjects became dippers. These differences
were not statistically significant.
Figure 3 shows the time course of response of body
fluid compartments and hormonal markers of volume
excess. ECW and TBW demonstrate significant decreases
between baseline and week 1, followed by a trend toward
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Fig. 2. Plasma renin activity (PRA) (A ) and plasma aldosterone (PA)
responses after multiple doses of torsemide and furosemide therapy
for each subject. Closed triangles represent treatment with torsemide;
open triangles represent treatment with furosemide. Box plots represent
the median, 10th, 25th, 75th, and 90th percentiles of each data set.
increasing values between weeks 1 and 3. Similarly, in
1 week BNP fell while PRA and PA increased; these
effects were maintained over 3 weeks.
An increase in PRA between baseline and 3 weeks
was negatively correlated with the change in ambulatory
systolic blood pressure (P 0.019). Thus, the greater the
renin response, the lower the blood pressure reduction.
DISCUSSION
The major findings of our study are (1) a reduction
in GFR is correlated with volume excess, (2) a single
dose of loop diuretic acutely induces significant volume
depletion but does not influence BNP or PA, and (3)
chronic administration of loop diuretics leads to dynamic
changes in body fluid compartments, hormonal changes,
and blood pressure lowering.
Increased ECW in CKD
Our data show that extracellular fluid (ECF) volume
expands as GFR is reduced. The finding of an expanded
Fig. 3. Time course of biophysical and hormonal measurements of
volume status during multiple dose study. *P  0.05 in comparison
with baseline measurements by analysis of variance (ANOVA) for
systolic blood pressure and Tukey honest significant test for other pa-
rameters. Multivariate ANOVA for all comparisons were significant.
ECF volume is consistent with the impaired natriuretic
response exhibited by patients with CKD after sodium
loading [7]. There is also greater increase in plasma vol-
ume relative to ECF volume in subjects with end-stage
renal disease than in subjects with normal kidney func-
tion when isotonic saline is administered [8].
Acute loop diuretic therapy and changes in body fluid
compartments and hormonal markers
We found that in subjects with CKD, loop diuretics
acutely induce volume depletion. Volume excess was
decreased primarily in the extracellular, but not intracel-
lular, compartment in response to a single dose of loop
diuretic. Our findings are consistent with observations
made in other volume excess states such as chronic liver
disease, where whole-body BIA revealed a significant
increase in both resistance and reactance after diuretic
treatment [9]. The decrease in resistance and/or reactance
measured by BIA found after volume depletion in our
study and others [9] is an expected finding after the loss
of electrolyte-rich water, which serves as a conduct-
ing medium for the current introduced by BIA analyz-
ers. Our study extends these observations to patients
with CKD.
Acutely, we found that volume depletion induced by
a single dose of loop diuretic was only accompanied by
a heterogeneous hormonal response. This difference in
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response of PRA, PA, and BNP may relate to nonvolume
regulatory and kinetic properties. We observed a dra-
matic increase in PRA after a single dose of loop diuretic.
This is consistent with observations in dogs where loop
diuretics increase PRA by both macula densa and baro-
receptor mechanisms [10]. Clinical studies have also
demonstrated PRA to increase after loop diuretic admin-
istration in both normotensive and hypertensive subjects
[11]. Interestingly, a single dose of loop diuretic did not
increase the concentration of PA. This effect is poten-
tially due to the significant decrease in serum potassium
evoked by the loop diuretic. Animal studies have estab-
lished that decreases in serum potassium directly lower
aldosterone synthesis by the adrenal cortex [12]. Plasma
BNP did not decrease after a single dose of diuretics
in our subjects. One explanation for this observation
involves a potential imbalance between peptide secre-
tion and clearance. While the stimulus for BNP secretion
by ventricular myocytes (left ventricular stretch and
afterload) may have been decreased by volume deple-
tion, BNP clearance may have likewise been decreased
by impaired kidney function [13]. Similar to atrial natri-
uretic peptide, BNP is predominantly cleared by natri-
uretic peptide receptor C and neutral endopeptidases,
both richly expressed in the kidney [14, 15]. The observa-
tion of decreased BNP clearance in kidney failure has
been observed in animal models, where human BNP
infused into rabbits after renal artery ligation had a lower
clearance and therefore a higher plasma concentration
than sham-operated animals [16].
Chronic loop diuretic therapy, changes in body fluid
compartments and hormonal markers and ambulatory
blood pressure
The presence of hypertension in CKD is related to
ECF volume [17], although mechanisms such as altered
vasodepressor and vasoconstrictor systems contribute as
well. The magnitude of increase in blood pressure in
response to ECF volume expansion is greater as renal
function declines [7, 17]. This interaction between vol-
ume excess and hypertension makes loop diuretics at-
tractive antihypertensive agents for CKD patients. In
our subjects, loop diuretics induced ECF volume reduc-
tion by 1 week, and led to reduction in ambulatory sys-
tolic blood pressure by 3 weeks. Changes in body fluid
compartments were accompanied by commensurate
changes in hormonal biomarkers.
The interactions between blood pressure reduction
and changes in ECF volume have been studied in depth
with thiazide diuretics. Studies done in patients with
essential hypertension more than 40 years ago show two
hemodynamic phases [18]. Acutely, over 5 to 19 days,
there is reduction in plasma volume (PV) and cardiac
output (CO) with concomitant increase in peripheral
vascular resistance (PVR). This is followed by a chronic
phase at least 1 month after treatment characterized by
restoration of PV and CO with simultaneous decrease
in PVR resulting in lowering of blood pressure [18].
These hemodynamic changes are maintained for at least
1 year [19]. Wilson and Freis [20] found that 4 days
of high-dose thiazide diuretics given to subjects with
essential hypertension produced blood pressure reduc-
tion that was associated with a significant decrease in
ECF volume and total body weight. This antihyperten-
sive effect was reversed with intravenous volume infu-
sion, indicating the volume-dependant mechanism of
blood pressure reduction. In contrast to the acute effects,
chronic blood pressure reduction with thiazide treatment
over 1 year occurred despite a return of ECF volume
to baseline values [20]. This normalizing volume trend
associated with blood pressure reduction with thiazide
diuretics have been shown by others over 4 to 6 months
of treatment [21, 22].
Other clinical trials also fail to demonstrate a chronic
decrease in plasma volume or change in body weight,
despite effective blood pressure reduction [23]. In pa-
tients with essential hypertension treated with thiazide
diuretics, responsiveness to infused norepinephrine is
blunted [24, 25]. This suggests alterations in systemic
vascular resistance in mediating blood pressure reduc-
tion [26]. Although both torsemide and furosemide re-
duced ambulatory blood pressure similarly, this effect
was not solely due to natriuresis, suggesting alternative
mechanisms of antihypertensive effect. Cell culture stud-
ies have suggested direct vascular effects of torsemide
that are independent of natriuresis. Torsemide inhibited
angiotensin II-induced protein synthesis in aortic vascu-
lar smooth muscle cell (VSMC) cultures from spontane-
ously hypertensive rats in a dose-dependent manner. The
authors suggested that torsemide might act at chloride
channels in VSMC, as angiotensin II stimulates the open-
ing of these channels, and the chemical structure of torse-
mide is similar to chloride channel blockers [27]. Thus,
torsemide may have vasodilatory properties. Human
studies also support mechanisms of antihypertensive ef-
fect of torsemide that are independent of natriuresis.
For example, trials in subjects with normal renal function
found that torsemide 2.5 mg daily (a dose under the
threshold to induce natriuresis) effected a similar de-
crease in both systolic blood pressure and diastolic blood
pressure as the thiazide diuretics indapamide [29] or
hydrochlorothiazide 25 mg/triamterene 50 mg [28]. These
studies agree with our findings that torsemide and furose-
mide reduce blood pressure by multiple mechanisms, and
lend support to the hypothesis that the antihypertensive
effect of torsemide and furosemide involves both volume
regulation and direct vascular effects.
The relationship between blood pressure–lowering
and renin-stimulating actions of loop diuretics in CKD
patients is consistent with prior observations in patients
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with essential hypertension. The observation that the
greater the renin response, the lower the blood pressure
decline, has been confirmed by other investigators [30, 31].
From the renin response, we can calculate the magnitude
of dietary sodium restriction to achieve the same results
to be 179 mEq/day (95% CI 163,199) [32]. As diuretic-
induced renin stimulation may be produced by both
baroreceptor and macula densa mechanisms, changes in
plasma aldosterone may better reflect a therapeutically
equivalent dose of sodium restriction. In our subjects,
this was calculated to be 91 mEq (95% CI 81,103) [32].
There are limitations to this study. First, our study
had a small sample size; therefore we have insufficient
statistical power to perform analysis on biomarkers that
may predict blood pressure lowering. Second, our subject
population was predominantly male, as they were re-
cruited from a Veterans Affairs hospital.
CONCLUSION
To summarize the mechanism of blood pressure reduc-
tion, we found that in subjects with stages 2 and 3 CKD,
ECF volume increases as the GFR decreases. This excess
in ECF volume can be corrected with loop diuretics. The
reduction in ECF volume results in stimulation of the
renin-angiotensin system within a few hours and reduc-
tion of BNP within a week. The reduction in ECF volume
is associated with reduction in ambulatory systolic blood
pressure by 3 weeks. Thus, acute ECF depletion triggers
the recruitment of homeostatic responses that translate
into chronic lowering of blood pressure even in patients
with CKD.
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